Intervention not reported
Disease‐free survival [range of median · patients with APL in first complete remission
The intervention leads to lower disease‐free survival [range of median (high certainty).
1 finding from 1 review
no estimate extracted
1209 participants
High
Intervention not reported
Adverse events requiring discontinuation [range of median · patients with APL in first complete remission
The intervention probably leads to lower adverse events requiring discontinuation [range of median (moderate certainty).
1 finding from 1 review
no estimate extracted
906 participants
Moderate
Intervention not reported
Relapse rate [range of median · patients with APL in first complete remission
The intervention probably leads to lower relapse rate [range of median (moderate certainty).
1 finding from 1 review
no estimate extracted
896 participants
Moderate
Intervention not reported
Overall survival [range of median · patients with APL in first complete remission
The intervention probably leads to lower overall survival [range of median (moderate certainty).
1 finding from 1 review
no estimate extracted
632 participants
Moderate
Intervention not reported
Disease‐free survival [range of median · patients with APL in first complete remission
The intervention leads to lower disease‐free survival [range of median (high certainty).
1 finding from 1 review
no estimate extracted
670 participants
High
Intervention not reported
Relapse rate [range of median · patients with APL in first complete remission
The intervention probably leads to lower relapse rate [range of median (moderate certainty).
1 finding from 1 review
no estimate extracted
425 participants
Moderate
Intervention not reported
Overall survival [range of median · patients with APL in first complete remission
The intervention probably leads to lower overall survival [range of median (moderate certainty).
1 finding from 1 review
no estimate extracted
1033 participants
Moderate
Intervention not reported
Disease‐free survival [range of median · patients with APL in first complete remission
The intervention leads to lower disease‐free survival [range of median (high certainty).
1 finding from 1 review
no estimate extracted
1028 participants
High
Intervention not reported
Overall survival · patients with cancer
The intervention showed no clear difference in overall survival (high certainty).
1 finding from 1 review
Intervention not reported
On‐study mortality Death occurring up to 30 days after active study protocol · patients with cancer
The intervention leads to higher on‐study mortality Death occurring up to 30 days after active study… (high certainty).
1 finding from 1 review
Intervention not reported
Thrombotic events · patients with cancer
The intervention probably leads to higher thrombotic events (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of Life ‐ Change in FACT‐Fatigue (13 items) FACT‐F 13 sub‐scale · patients with cancer
1 finding from 1 review
Intervention not reported
Quality of Life ‐ Change in FACT‐Anaemia (20 items) FACT‐An 20 · patients with cancer
1 finding from 1 review
Intervention not reported
Participants receiving red blood cell transfusions · patients with cancer
The intervention probably leads to lower participants receiving red blood cell transfusions (moderate certainty).
1 finding from 1 review
Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
Prophylactic platelet transfusion showed no clear difference in bleeding: Numbers of patients with at least one significant bleeding… compared with non prophylactic or therapeutic platelet transfusion (low certainty).
1 finding from 1 review
Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
Prophylactic platelet transfusion with one dose schedule showed no clear difference in bleeding Number of participants with a significant bleeding event ‐… compared with prophylactic platelet transfusions with another dose schedule (high certainty).
2 findings from 1 review
Bleeding Number of days with significant bleeding ‐ Low dosage platelet transfusions versus standard dosage platelet transfusions · People with a haematological disorder
1 finding from 1 review
Bleeding: Number of days with significant bleeding ‐ High dosage platelet transfusions versus standard dosage platelet transfusions · People with a haematological disorder
1 finding from 1 review
Mortality: secondary to bleeding · People with a haematological disorder
2 findings from 1 review
Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
It is very uncertain whether prophylactic platelet transfusion changes number of participants with a significant bleeding event compared with platelet‐poor plasma (very low certainty).
1 finding from 1 review